Most popular articles on this site Articles on pharmacy Articles on capitation Articles on disease management

www managedcaremag.com





NOW AVAILABLE
The next generation in online publishing...

Requires
Flash Player 9

Version Test
Download Flash


Sign up to read the digital versions of Managed Care, P&T, and Biotechnology Healthcare. These digital editions are free, searchable, and can be downloaded and read offline. To read a sample of the digital version of Managed Care, follow this link:

Sample digital edition

Register for a free digital subscription

Archive issues of Managed Care:

Supplement to Managed Care:
Continuing Education Credit

Mind Your Body: The Intersection of Physical and Behavioral Health
Free download
MANAGED CARE November 2005. ©MediMedia USA
NEWS AND COMMENTARY

Plans Change Tactics As Costs Keep Rising For Specialty Drugs

Based on the current trend, with specialty drug costs growing annually by 20 percent, they will account for more than a quarter of all outpatient pharmacy expenditures by 2008. These findings were reported in CuraScript's Specialty Pharmacy Management Guide and Trend Report, an annual guide highlighting the effects of specialty drug costs on employers' health care plans.

Average drug copayments for preferred ($22), nonpreferred ($35), and generic ($10) drugs have increased slightly over 2004 levels. Nevertheless, drug copayments for fourth-tier drugs, typically biotech and "lifestyle" drugs, increased 54 percent in 2005, according to survey results.

CuraScript reports that in an effort to get a handle on rising medical costs, a significant number of their clients are saving by ensuring that self-administered drugs are not administered in the physician's office, unless the patient's health status prevents self-administration. The report indicates a shift away from covering specialty drugs under the medical benefit, regardless of whether they are administered by the patient or by a clinician.

CuraScript expects to see a significant shift in the percentage of plans exclusively classifying specialty drugs under the medical benefit. By the end of 2005, the number of clients classifying specialty drugs under the pharmacy benefit will more than double, and specialty products covered under the medical benefit are expected to be cut in half.